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The purpose of this study was to develop Cremophor® EL-free nanoparticles loaded with Paclitaxel (PTX), 
intended to be intravenously administered, able to improve the therapeutic index of the drug and devoid of the 
adverse effects of Cremophor® EL. PTX-loaded PEGylated PLGA-based were prepared by simple emulsion and 
nanoprecipitation. 
The incorporation efficiency of PTX was higher with the nanoprecipitation technique. The release behavior of 
PTX exhibited a biphasic pattern characterized by an initial burst release followed by a slower and continuous 
release. The in vitro anti-tumoral activity was assessed using the Human Cervix Carcinoma cells (HeLa) by the 
MTT test and was compared to the commercial formulation Taxol® and to Cremophor® EL. When exposed to 
25µg/mlof PTX, the cell viability was lower for PTX-loaded nanoparticles than for Taxol® (IC50 5.5 vs 15.5 µg/ 
ml). Flow cytometry studies showed that the cellular uptake of PTX-loaded nanoparticles was concentration and 
time dependent. Exposure of HeLa cells to Taxol® and PTX-loaded nanoparticles induced the same percentage 
of apoptotic cells. PTX-loaded nanoparticles showed greater tumor growth inhibition effect in vivo on TLT 
tumor, compared with Taxol®. Therefore, PTX-loaded nanoparticles may be considered as an effective 
anticancer drug delivery system for cancer chemotherapy. 
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1. INTRODUCTION 
Paclitaxel (PTX), a major anticancer drug isolated from the bark of Taxus brevifolia, has antineoplasic activity 
particularly against various types of solid tumors. PTX is approved in many countries for its use as second line 
treatment of ovarian and breast cancers [1,2]. PTX has a unique mechanism of action. It disrupts the dynamic 
equilibrium within the microtubule system and blocks cells in the late G2 phase and M phase of the cell cycle, 
thereby inhibiting cell replication [3]. It has been reported that Taxol® induces bcl2 phosphorylation followed by 
apoptosis [4]. PTX is poorly soluble in water [5]. To enhance its solubility and allow parenteral administration, 
PTX is currently formulated (Taxol®) at 6 mg/ml in a vehicle composed of 1:1 blend of Cremophor® EL and 
ethanol. However, Cremophor® EL causes side effects e.g. hypersentivity, nephrotoxicity and neurotoxicity as 
well as effects on endothelial and vascular muscles causing vasodilatation, labored breathing, lethargy and 
hypotension [6], 
Numerous investigations have shown that both tissue and cell distribution profiles of anticancer drugs can be 
controlled by their entrapment in submicronic colloidal systems. Accordingly, a number of alternative 
formulations were investigated for the solubilization of PTX, including liposomes, microspheres, nanoparticles 
and polymeric micelles [7-10]. The rationale behind this approach is to increase antitumor efficacy while 
reducing systemic side effects [11]. Nano-particulate drug delivery systems have been studied for several 
decades now, and many of the features that make them attractive drug carriers are well known. Moreover, 
nanoparticles can escape from the vasculature through the leaky endothelial tissue that surrounds the tumor and 
then accumulate in certain solid tumors by the so-called Enhanced Permeation and Retention (EPR) effect [12]. 
A Cremophor-free formulation of PTX nanoparticles, Abraxane®, has recently been approved by the FDA for 
recurrent metastatic breast cancer [13]. 
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The aim of this study was to develop a polymeric drug delivery system for PTX, Cremophor® EL-free, intended 
to be intravenously administered. To achieve this aim, PTX-loaded PEGylated PLGA-based nanoparticles were 
prepared by nanoprecipitation method [14]. Poly(lactide-co-glycolide) (PLGA) was chosen for its 
biodegradability properties, its biocompatibility and its approval by FDA. Poly(ε-caprolactone-co-ethylene 
glycol) (PCL-PEG), an amphiphilic copolymer, was added to take advantage of PEG repulsive properties [15,16] 
and to provide a higher stability of nanoparticles in biological fluids [17]. The nanoparticles were characterized 
in terms of size and charge. In vitro drug release was evaluated. In vitro anti-tumoral activity of PTX-loaded 
nanoparticles was performed using Human Cervix Carcinoma cells (HeLa). In vitro cellular uptake and apoptosis 
were also studied. Finally, in vivo tumor growth inhibition of PTX-loaded nanoparticles was also investigated in 
TLT-tumor bearing mice. 
2. MATERIALS AND METHODS 
2.1. Materials 
PCL-PEG, PLGA, PLGA-PEG and PLGA-FITC polymers were synthesized by ring opening polymerization 
[16]. Molecular weights were determined by size exclusion chromatography (SEC) and NMR as described 
previously (Table 1). 
PTX was purchased from Calbiochem (Darmstadt, Germany). Taxol® (Brystol-Myers Squibb) was obtained 
from Cliniques Universitaires Saint-Luc, Belgium. Taxol® contains 6 mg/ml of PTX and 528 mg/ml of 
Cremophor® EL. 
HeLa (Human Cervix Carcinoma) cells were acquired from ATCC (American Type Culture Collection, 
Manassas, VA, USA). Cremophor® EL, 4,6-diamidino-2-phenylindole (DAP1) and 3-(4, 5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide) (MTT) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Dubelcco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), trypsin-EDTA and penicillin-
streptomycin mixtures were from Gibco® BRL (Carlsbad, CA, USA). Ultra-purified water was used throughout 
and all other chemicals were of analytical grade. 
NMR1 mice were purchased from Janvier, Genest St Isle, France. 
2.2. Preparation of Paclitaxel-loaded nanoparticles 
First, nanoparticles were prepared by simple emulsion technique [18]. Briefly, 7.5 mg of PLGA-PEG in 500 µl 
of dichloromethane and 7.5 mg of PCL-PEG in 500 µl of dichloromethane were added to 35 mg of PLGA. 2 mg 
of PTX was mixed with the polymer solution. 2 ml of sodium cholate 1% was added before a sonication of 15 s 
(70 W). The emulsion formed was added dropwise on 100 ml of sodium cholate 0.3% under magnetic stirring. 
To evaporate dichloromethane, the solution was stirred 45 min at 37 °C. 
Nanoparticles were also prepared by the interfacial deposition method (nanoprecipitation) [14]. Briefly, an 
organic solution of PLGA (70 mg), PLGA-PEG (15 mg), PCL-PEG (15 mg) and PTX (1 mg) in 10 ml acetone 
was added to 20 ml of water under magnetic stirring at room temperature overnight to allow the evaporation of 
acetone. 
To remove the non-encapsulated drug, the suspensions were filtered (1.2 µm) and ultracentrifuged at 22.000 g 
for 1 h at 4 °C. The pellets were suspended in 10 ml of ultra-purified water. 
Table 1: Chemical description of the polymers included in the formulations 
Polymer Mn (SEC)a g/mol Mn (NMR) g/molb 
PLGA 22,000  
PLGA-FITC 23,600  
PLGA-PEG 29,300 16,500-4600 
PCL-PEG 22,400 15,200-4600 
a
 Polystyrene calibration. 
b
 Determined by NMR by the following formula: (I4.7/2)/(I5.2+I4.7/2))x100, where I4.7, is the signal intensity of the glycolide unit at 4.7 ppm 
(CH2OC=O) and I5.2 is the signal intensity of the lactide unit at 5.2 ppm (CH(CH3)OC=O). 
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2.3. Determination of Paclitaxel content in nanoparticles 
The drug loading efficiency was determined in triplicate by HPLC (Agilent 1100 series, Agilent Technologies, 
Diegem, BE). The mobile phase consisted in acetonitrile/water (70:30 v/v). The reverse phase column was a 
CC125/4 Nucleod UR100-5 C18. The column temperature was maintained at 30 °C. The flow rate was set at 1.0 
ml/min and the detection wavelength was 227 nm. Sample solution was injected at a volume of 50 µl. The HPLC 
was calibrated with standard solutions of 5 to 100 µg/ml of PTX dissolved in acetonitrile (correlation coefficient 
of R2=0.9965). The limit of quantification was 0.6 ng/ml. The coefficients of variation (CV) were all within 
4.3%. Nanoparticles were dissolved in acetonitrile and vigorously vortexed to get a clear solution.                    
The encapsulation efficiency was defined by the ratio of measured and initial amount of PTX encapsulated in 
nanoparticles [19], 
 
The recovery corresponds to the ratio of the amount of PTX in the supernatant and in the pellets to the initial 
amount of PTX. 
 
2.4. Physicochemical characterization of Paclitaxel-loaded nanoparticles 
The average particle size and size polydispersity of the nanoparticles prepared in water were determined by 
photon correlation spectroscopy in water using a Malvern Nano ZS (Malvern Instruments, UK). ζ Potential of 
nanoparticles was measured in KCL 1mM with a Malvern Nano ZS (Malvern Instruments, UK) at 25 °C. The 
instrument was calibrated with standard latex nanoparticles (Malvern Instruments, UK). Experimental values 
were the average of 3 different formulations. 
2.5. In vitro drug release 
PTX-loaded nanoparticles ( 1 mg of PTX) were dispersed in 10.0 ml of PBS (phosphate buffer solution, pH 7.4) 
and incubated at 37 °C under magnetic stirring. At determined time intervals, the tube was ultracentrifuged at 
22.000 g for 1 h at 4 °C. 1 ml of supernatant mixed with 1 ml of acetonitrile was analyzed by HPLC as described 
in Section 2.3 [20]. 
2.6. In vitro anti-tumoral activity 
HeLa cells were grown in DMEM supplemented with 10% (v/v) fetal bovine serum and 100 IU/ml of penicillin 
G sodium and 100 µg/ml of streptomycin sulfate. The cells were maintained in an incubator supplied with 5% 
CO2/95% air humidified atmosphere at 37 °C. 
Table 2: Influence of the preparation method on the encapsulation efficiency, the recovery rate and on the 
physicochemical characteristics (n = 3) 
 Simple emulsion Nanoprecipitation 
PTX encapsulation efficiency (%) 37 ±2.5 70 ± 4 
PTX/polymers (%) 0.4 ± 0.02 0.7 ±0.04 
PTX recovery (%) 78 ±3 96.7 ±1.6 
Size (nm)a 190 ± 4.5 112±4 
PDP 0.16 ± 0.002 0.18 ± 0.005 
ζ potential (mV)b -7.76 ± 2.6 -0.556 ± 5.7 
ζ deviation (mV)b 6.18 ± 0.98 6.46 ± 1.02 
a
 Measured by photon correlation spectroscopy with a Malvern Nano ZS. b Determined with a Malvern Nano ZS. 
HeLa cells were seeded in 96-well plates at the density of 2500 viable cells per well and incubated 24 h to allow 
cell attachment. The cells were then incubated with Taxol®, PTX-loaded nanoparticles (PTX concentrations of 
0.025, 0.25, 2.5, 12.5 and 25 µg/ml at a PTX/polymers percentage of 0.7%), Cremophor® EL (0.022 to 2.2 
mg/ml) and drug-free nanoparticles (polymers concentration 10 mg/ml) for 24, 48 and 72 h. At determined time, 
the formulations were replaced with DMEM containing MTT (5 mg/ml) and cells were then incubated for 
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additional 4 h. MTT was aspirated off and DMSO was added to dissolve the formazan crystals [21 ]. Absorbance 
was measured at 570 nm using a BioRad microplate reader. Untreated cells were taken as control with 100% 
viability and cells without addition of MTT were used as blank to calibrate the spectrophotometer to zero 
absorbance. Triton X-100 1% was used as positive control of cytotoxicity [22]. The results were expressed as 
mean values +⁄- standard deviation of 5 measurements. 
2.7. In vitro cellular uptake of nanoparticles 
Fluorescent nanoparticles were prepared by incorporating PLGA-FITC instead of PLGA in the formulations as 
described in Section 2.2. Twelve-well plates were seeded with 100000 HeLa cells per well and the cells were 
incubated at 37 °C for 24 h to allow cell attachment. After 24 h, the medium was replaced by PTX-loaded 
nanoparticles (PTX concentrations 2.5, 12.5 and 25 µg/ml) for 30 min, 2 h and 24 h. After incubation, the 
nanoparticles were removed and the wells were washed with ice-cold PBS. The cells were then harvested by 
trypsinization and centrifuged at 254 g for 5 min at 4 °C. Finally, the cells were resuspended in 500 µl of PBS 
and stored on ice until analysis. The percentage of fluorescent cells in the population and the fluorescence 
intensity were measured using a flow cytometer (FACScan, Becton Dickinson). Data were analyzed using the 
CellQuest (Becton Dickinson) software. The individual fluorescence of 10.000 cells was collected for each 
sample [23]. The counting of nanoparticles number was also determined by flow cytometry [16], 
2.8. Apoptosis induced by PTX-loaded nanoparticles 
Apoptosis was identified morphologically by 4,6-diamidino-2-phenylindole (DAP1) staining. HeLa cells were 
seeded in 6-well plates containing a coverslip with 100000 cells per well and cultured at 37 °C for 24 h. Cells 
were then incubated for 4 h with Taxol®, PTX-loaded nanoparticles (PTX concentration of 25 µg/ml) and culture 
medium as control. Samples were then fixed with 4% paraformaldehyde in PBS at room temperature for 15 min, 
stained with 0.2 µg/ml DAP1 in PBS at room temperature for 15 min and washed twice with PBS and with 
water. Coverslips were mounted onto glass slides. Slides were then examined using a fluorescent microscope 
with a 340/380 nm excitation filter and LP 430 nm barrier filter. Enumeration of apoptotic nuclei (about 200 
cells were counted) was made on slides picked up at random by two independent experimenters. Clusters of 
apoptotic bodies were given as a single count [24], 
2.9. In vivo tumor growth inhibition study 
The transplantable liver tumor TLT was implanted in the gastrocnemius muscle in the posterior leg of 8 weeks 
old male NMRI mice. All experiments were approved by the ethical committee for animal care of the faculty of 
medicine of the Université Catholique de Louvain. 
The effect of PTX-loaded nanoparticles on TLT growth was assessed by measuring daily the diameter of the 
tumors with an electronic caliper. When tumors reached 8.0 ±0.5 mm in diameter, the mice were randomly 
assigned to a treatment group. Three groups of mice (6 mice per group) were treated: group 1: PBS injection; 
group 2: Taxol® ((PTX concentration of 1 mg/kg; diluted in PBS); group 3: PTX-loaded nanoparticles (PTX 
concentration of 1 mg/kg). The treatments were injected through the tail vein. After treatment, tumors were 
measured every day until they reached a diameter of 18 mm, at which time the mice were killed. Body weight 
change was also monitored. 
2.10. Statistics 
All results are expressed as mean ± standard deviation. One-way or Two-way ANOVA and Bonferroni post test 
were performed to demonstrate statistical differences (p<0.05); IC50 values were calculated from a dose-response 
graph (not shown) with sigmoidal function with variable Hill slope, using the software GraphPad Prism 5 for 
Windows. Survival curves were also calculated from the software GraphPad Prism 5 for Windows. 
3. RESULTS AND DISCUSSION 
3.1. Physicochemical characterization of Paclitaxel-loaded nanoparticles 
Chemical description of polymers used in the formulations is summarized in Table 1. The influence of the 
preparation method on the incorporation efficiency and on the recovery rate is illustrated in Table 2. 
Nanoparticles prepared with the nanoprecipitation method could achieve higher incorporation efficiency (70%) 
than with the simple emulsion technique (37%). The loss of PTX was also higher with the simple emulsion 
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technique. Hence, the nanoprecipitation method was chosen for the formulation of PLGA based PEGylated 
nanoparticles. 
Nanoparticles obtained by simple emulsion and nanoprecipitation were characterized in term of size and ζ 
potential (Table 2). Nanoprecipitation technique generated nanoparticles smaller than those obtained with the 
simple emulsion technique (112 vs 190 nm). With both techniques, nanoparticles exhibited a narrow size 
distribution (polydispersity index<0.2). Nanoparticles obtained by both techniques exhibited a ζ potential close 
to neutrality, confirming the presence of PEG chains shielding the negative charges present at the nanoparticle 
surface. 
Consistent with previously published data [16,25], the presence of PTX compared to free-drug nanoparticles did 
not affect the size and the ζ potential of nanoparticles (data not shown). 
3.2. In vitro drug release 
The in vitro release profile of PTX-loaded nanoparticles was investigated in PBS at 37 °C. The cumulative 
percentage release is shown in Fig. 1. After the initial burst release for about 4 h, the release rate of PTX slowed 
down and became an almost zero-order rate of release (R2=0.97 ). PTX released in the first 4 h was equivalent to 
46.9 ± 5.7% of the initial drug load of nanoparticles. After 11 days, the amount of cumulated PTX release was 
75.3 ± 2.7%. The burst release of PTX may be due to the dissolution and diffusion of the drug that was poorly 
entrapped in the polymer matrix, while the slower and continuous release may be attributed to the diffusion of 
the drug localized in the PLGA core of the nanoparticles. Similar burst effect was observed previously [18,26]. 
Fig. 1: Cumulative PTX release from PTX-loaded PLGA/PCL-PEG nanoparticles.                                                     
At preselected time intervals, the release PTX was separated by ultracentrifugation and the amount of PTX was measured by HPLC as 
described in Section 2.5 (n=3). 
 
 
3.3. In vitro anti-tumoral activity 
The in vitro cytotoxic activity of Taxol®, Cremophor® EL, drug-free nanoparticles and PTX-loaded nanoparticles 
was evaluated by the MTT assay using the HeLa cell line. The range of concentrations of PTX (0.025 to 25 
µg/ml) corresponds to plasma levels of the drug achievable in humans [27], The range of concentrations of 
Cremophor® EL (0.022 to 2.2 mg/ml) corresponds to the concentrations present in solution of different 
concentrations of Taxol® tested. 
At the concentration of 25 µg/ml Taxol®, cell viability lower than 8% was achieved after 24 h while lower PTX 
concentrations achieved the same low cell viability after 48 h. The IC50 at 24 h was 15.5 µg/ml (Fig. 2A). 
As reported previously [28,29], Cremophor® EL was cytotoxic at concentration above 1 mg/ml. (Fig. 2B). 
When encapsulated in nanoparticles, 25 and 12.5 µg/ml PTX totally inhibited cell viability after 24 h of 
incubation while a 40% decrease in cell viability was achieved at lower concentrations of PTX (2.5 to 0.025 
µg/ml). IC50 value for HeLa cells decreased from 15.5 µg/ml for Taxol® to 5.5 µg/ml for the PTX-loaded 
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nanoparticles after 24 h incubation. At 12.5 µg/ml and 2.5 µg/ml PTX, PTX-loaded nanoparticles contributed to 
higher reduction in cell viability than Taxol® (p<0.01 and 0.05 respectively) (Fig 2D). Cell viability was totally 
suppressed after 48 h of incubation. No cytotoxic activity was observed for the drug-free nanoparticles at 10 
mg/ml polymers. 
It should be emphasized that in the case of Taxol® a significant effect was attributed to the excipient Cremophor® 
EL(absent in nanoparticles), whereas in the case of PTX-loaded nanoparticles the cytotoxicity observed was only 
attributed to PTX (drug-free nanoparticles were non-cytotoxic). This decrease in cell viability, measured by the 
MTT test can result from an inhibition of cell growth or from cytotoxicity. 
Both incubation time and concentration played a major role in the in vitro cytotoxicity of PTX. For longer 
incubation periods a larger number of cells enter the G2 and M cell cycle phases during which PTX is more 
active [3], During the first 24 h of incubation, the significant amount of free PTX released from the nanoparticles 
could be available to mediate some cytotoxicity. Nevertheless, the cytotoxic effect may be a result of the 
presence of free PTX, or PTX-loaded nanoparticles or a combination of both. 
Consistent with other published data, the incorporation of PTX into nanoparticles enhanced its anti-tumoral 
activity compared to Taxol® [30], showing smaller IC50 over Taxol® [20], 
 
Fig. 2: Viability of HeLa cells with (A) Taxol®, (B) Cremophor® EL and (C) PTX-loaded nanoparticles.               
Cells were incubated with different concentrations for 1, 2 and 3 days as described in Section 2.6. (D) Viability of HeLa cells incubated for 
24 h with Taxol® (PTX concentrations: 25, 12.5 and 2.5 µg/ml), Cremophor® EL (concentrations corresponding to Taxol® formulation: 2.2, 
1.1 and 0.22 mg/ml), PTX-loaded nanoparticles (PTX concentrations: 25, 12.5 and 2.5 µg/ml) and drug-free nanoparticles (polymers 
concentration 10 mg/ml). Cell viability was determined by the MTT assay. Untreated cells were taken as negative control and Triton X-100 
1% was used as positive control. The results are expressed as mean values t standard deviation of 5 measurements of two independent 
experiments. *p<0.05, ** p<0.01. 
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3.4. In vitro cellular uptake of nanoparticles 
To check if the drug-loaded nanoparticles were internalized in tumor cells, the cellular uptake of PTX-loaded 
nanoparticles was evaluated on HeLa cells at different time intervals and different concentrations of PTX using 
flow cytometry. The percentage of cells that showed an increase of fluorescence compared to the untreated 
control cells and the fluorescence intensity are shown in Fig. 3. 
As the nanoparticles contained the same ratio of PTX/polymers, the increase of PTX concentrations from 2.5 to 
25 µg/ml lead to an increase in polymer concentration and nanoparticles number from approximately 108/ml to 
109/ml. The uptake of the nanoparticles loaded with 25 µg/ml of PTX was very fast: 98% of the cells were 
fluorescent after 30 min. After 2 and 24 h, the percentage of fluorescent cells was the same, 99% respectively 
(p>0.05). The fluorescence intensity increased with the incubation time (p<0.05). The profile of cellular uptake 
of nanoparticles loaded with 12.5 µg/ml of PTX was the same than for nanoparticles loaded with 25 µg/ml of 
PTX. For nanoparticles loaded with 2.5 µg/ml of PTX, the percentage of fluorescent cells increased with the 
incubation time (p<0.05). The cellular uptake of PTX-loaded nanoparticles was time-dependent. The percentage 
of fluorescent cells and the fluorescence intensity increased with the concentration of the nanoparticles (p<0.05). 
The cellular uptake of PTX-loaded nanoparticles was thus also concentration-dependent. 
 
Fig. 3: Cellular uptake of PTX-loaded nanoparticles containing PLGA-FITC (PTX concentration of 2.5, 12.5 
and 25 µg/ml).                                                                                                                                                            
Cells incubated with PBS and culture medium were taken as control. (A) Percentage of cells exhibiting fluorescence associated with PLGA-
FITC at different time intervals (n=4). (B) Fluorescence intensity associated with cells at different time intervals (n=4). *p<0.05. 
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These results are in accordance with those of anti-tumoral activity studies: almost total inhibition of cell viability 
and high cellular uptake were achieved after 24 h incubation. Generally, nanoparticles are non-specifically 
internalized into cells via endocytosis or phagocytosis [31,32]. Nevertheless, it is possible that the FITC-labeled 
nanoparticles were not internalized in cells but adsorbed non-specifically to the surface of the cells. Other 
experiments should be carried out in order to distinguish these two mechanisms. 
3.5. Apoptosis induced by PTX-loaded nanoparticles 
To examine if the encapsulation of PTX in nanoparticles modify the apoptosis induced by PTX, DAP1 staining 
of DNA was performed [33]. The nuclei of untreated HeLa cells showed homogenous fluorescence with no 
evidence of segmentation and fragmentation after DAP1 staining. Exposure of the cells for 4 h at 37 °C to 
Taxol® and PTX-loaded nanoparticles (25 µg/ml of PTX) led to segregation of the cell nuclei into segments, 
indicating breakdown in the chromatin followed by DNA condensation. The percentage of apoptotic cells 
induced by Taxol® and PTX-loaded nanoparticles was not significantly different indicating that nanoparticles did 
not affect the mechanism of action of PTX compared to Taxol® (Fig. 4). PTX encapsulated in the nanoparticles 
or released in the extracellular medium was able to induce apoptosis. Similar results were observed for other 
PTX concentration (12.5 and 2.5 µg/ml) and incubation time (8 h) (data not shown). 
 
Fig. 4: DAPI staining of HeLa cells after incubation for 4 h of culture medium as control, Taxol® and PTX-
loaded nanoparticles (PTX concentration 25 µg/ml).                                                                                                    
(A) Percentage of apoptotic cells (DAPI staining). Enumeration of apoptotic nuclei (about 200 cells were counted) was made on slides 
picked up at random by two independent experimenters. Clusters of apoptotic bodies were given as a single count (B) Untreated cells as 
control. (C) Taxol®. (D) PTX-loaded nanoparticles. (For interpretation of the references to colour in this figure legend, the reader is referred 
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Fig. 5: (A) Antitumor effect of PTX-loaded nanoparticles and Taxol® on TLT tumor-bearing mice.                     
One week after intramuscular TLT tumor implantation, treatments were injected intravenously. Untreated control received PBS injection; the 
treatments groups consisted in PTX-loaded nanoparticles and Taxol® (PTX concentration 1 mg/kg). Each point represents the mean of tumor 




3.6. In vivo tumor growth inhibition study 
The in vivo anti-tumor efficacy of PTX-loaded nanoparticles and Taxol® was evaluated in TLT tumor-bearing 
mice. The PTX-loaded nanoparticles inhibited tumor growth most efficiently, followed by Taxol® (p< 0.05 )       
( Fig. 5A). The study on the control ( PBS ) group ended on the 7th day because the tumor volume was 
excessively enlarged (about 18 mm), while other groups lasted until the 11th day for Taxol® and the 14th day for 
PTX-loaded nanoparticles (p<0.001 ) (Fig. 5B). Body weight measurements showed no significant differences 
between the groups throughout the study. There was a slight increase in body mass as a result of natural animal 
growth (data not shown). 
When encapsulated into nanoparticles, PTX could attain tumor site through EPR effect and maintain the 
effective therapeutic concentration for a long period of time. The nanoparticle formulations allowed to suppress 
the use of Cremophor® EL which causes serious adverse effects. 
4. CONCLUSION 
The aim of the study was to design polymeric nanoparticles loaded with the anticancer drug PTX. PTX-loaded in 
the nanoparticles were more cytotoxic on Hela cells than Taxol®. However in contrast to Cremophor® EL, no 
cytotoxicity of the polymers was observed. Apoptosis induced by the PTX-loaded nanoparticles and Taxol® was 
similar. Cellular uptake of PTX-loaded nanoparticles was concentration and time dependent. In mice, PTX-
loaded nanoparticles showed noticeable anti-tumor efficacy and enhanced survival rates, compared to Taxol®. 
Based on these results, it can be concluded that the formulations developed in this work may be considered as an 
effective anticancer drug delivery for cancer chemotherapy. 
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